| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Added therapeutic benefit regarding ESMO-MCBS and the French health technology assessment of drugs granted early access program
|
Pham, F.Y.-V.
|
|
|
33 |
5 |
p. 561-563
|
artikel
|
| 2 |
Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF V600 mutation–positive melanoma
|
Robert, C.
|
|
|
33 |
5 |
p. 544-555
|
artikel
|
| 3 |
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|
Moschini, M.
|
|
|
33 |
5 |
p. 561
|
artikel
|
| 4 |
Editorial Board
|
|
|
|
33 |
5 |
p. iii
|
artikel
|
| 5 |
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data
|
Pérol, M.
|
|
|
33 |
5 |
p. 511-521
|
artikel
|
| 6 |
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
|
Passaro, A.
|
|
|
33 |
5 |
p. 466-487
|
artikel
|
| 7 |
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies
|
Subbiah, V.
|
|
|
33 |
5 |
p. 522-533
|
artikel
|
| 8 |
FIGHT against FGF/FGFR alterations: what are the next steps?
|
Bayle, A.
|
|
|
33 |
5 |
p. 460-462
|
artikel
|
| 9 |
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
|
Peters, S.
|
|
|
33 |
5 |
p. 488-499
|
artikel
|
| 10 |
Paradigms for the development of transformative medicines—lessons from the EGFR story
|
Pao, W.
|
|
|
33 |
5 |
p. 556-560
|
artikel
|
| 11 |
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study ☆
|
Gianni, L.
|
|
|
33 |
5 |
p. 534-543
|
artikel
|
| 12 |
Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer
|
Di Noia, V.
|
|
|
33 |
5 |
p. 563-565
|
artikel
|
| 13 |
‘Rare cancers’: not all together in clinical studies!
|
Casali, P.G.
|
|
|
33 |
5 |
p. 463-465
|
artikel
|
| 14 |
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
|
Gale, D.
|
|
|
33 |
5 |
p. 500-510
|
artikel
|
| 15 |
Table of Contents
|
|
|
|
33 |
5 |
p. i-ii
|
artikel
|
| 16 |
VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
|
Tutt, A.N.J.
|
|
|
33 |
5 |
p. 566-568
|
artikel
|
| 17 |
3-Year CheckMate743 outcomes: ringing in immunotherapy for the treatment of malignant pleural mesothelioma
|
Cedres, S.
|
|
|
33 |
5 |
p. 457-459
|
artikel
|
Tijdschrift beschrijving